VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic Lymphocytic Leukemia

Molecular Therapy

Volumn 18, Issue 12, 2010, Pages 2094-2103

  Samuel, Sara ^a,b   Tumilasci, Vanessa F ^a,b   Oliere, Stephanie ^a,b   Liên Anh Nguyên, Thi ^a   Shamy, April ^c   Bell, John ^d   Hiscott, John ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; OBATOCLAX; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN SECRETION; PROTEIN TRANSPORT; SCID MOUSE; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 78650896361     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.188     Document Type: Article

References (50)

1. Caligaris-Cappio, F and Hamblin, TJ (1999). B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17: 399-408.
2. Herishanu, Y and Polliack, A (2005). Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors infuencing prognosis and therapeutic options. Transfus Apher Sci 32: 85-97.
3. Inamdar, KV and Bueso-Ramos, CE (2007). Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol 11: 363-389.
4. Craig, RW (2002). MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454.
5. Pepper, C, Lin, TT, Pratt, G, Hewamana, S, Brennan, P, Hiller, L et al. (2008). Mcl-1 expression has in vitro and in vivo signifcance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112: 3807-3817.
6. Johnston, JB, Paul, JT, Neufeld, NJ, Haney, N, Kropp, DM, Hu, X et al. (2004). Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 45: 2017-2027.
7. Kitada, S, Andersen, J, Akar, S, Zapata, JM, Takayama, S, Krajewski, S et al. (1998). Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91: 3379-3389.
8. Chipuk, JE, Moldoveanu, T, Llambi, F, Parsons, MJ and Green, DR (2010). The BCL-2 family reunion. Mol Cell 37: 299-310.
9. Kang, MH and Reynolds, CP (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132.
10. Brunelle, JK and Letai, A (2009). Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122(Pt 4): 437-441.
11. Willis, SN, Fletcher, JI, Kaufmann, T, van Delft, MF, Chen, L, Czabotar, PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
12. Vogler, M, Weber, K, Dinsdale, D, Schmitz, I, Schulze-Osthoff, K, Dyer, MJ et al. (2009). Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16: 1030-1039.
13. Campàs, C, Cosialls, AM, Barragán, M, Iglesias-Serret, D, Santidrián, AF, Coll-Mulet, L et al. (2006). Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 34: 1663-1669.
14. High, LM, Szymanska, B, Wilczynska-Kalak, U, Barber, N, O'Brien, R, Khaw, SL et al. (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77: 483-494.
15. Mason, KD, Khaw, SL, Rayeroux, KC, Chew, E, Lee, EF, Fairlie, WD et al. (2009). The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23: 2034-2041.
16. Nguyen, M, Marcellus, RC, Roulston, A, Watson, M, Serfass, L, Murthy Madiraju, SR et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517.
17. Li, J, Viallet, J and Haura, EB (2008). A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 61: 525-534.
18. Reed, JC and Pellecchia, M (2005). Apoptosis-based therapies for hematologic malignancies. Blood 106: 408-418.
19. Trudel, S, Li, ZH, Rauw, J, Tiedemann, RE, Wen, XY and Stewart, AK (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438.
20. Witters, LM, Witkoski, A, Planas-Silva, MD, Berger, M, Viallet, J and Lipton, A (2007). Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/ neu and a Bcl-2 inhibitor. Oncol Rep 17: 465-469.
21. Pérez-Galán, P, Roué, G, Villamor, N, Campo, E and Colomer, D (2007). The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109: 4441-4449.
22. Lichty, BD, Stojdl, D F, Taylor, RA, Miller, L, Frenkel, I, Atkins, H et al. (2004). Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 15: 821-831.
23. Tumilasci, VF, Olière, S, Nguyên, TL, Shamy, A, Bell, J and Hiscott, J (2008). Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 82: 8487-8499.
24. Msaouel, P, Iankov, ID, Allen, C, Morris, JC, von Messling, V, Cattaneo, R et al. (2009). Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69: 82-91.
25. Goubau, D, Romieu-Mourez, R, Solis, M, Hernandez, E, Mesplède, T, Lin, R et al. (2009). Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur J Immunol 39: 527-540.
26. Lallemand, C, Blanchard, B, Palmieri, M, Lebon, P, May, E and Tovey, MG (2007). Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifcations of IRF-1, IRF-3 and CREB. Oncogene 26: 328-338.
27. Sun, Y and Leaman, DW (2005). Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 280: 15561-15568.
28. Gaddy, DF and Lyles, DS (2007). Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 81: 2792-2804.
29. Gaddy, DF and Lyles, DS (2005). Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79: 4170-4179.
30. Riedl, SJ and Shi, Y (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.
31. Billen, LP, Shamas-Din, A and Andrews, DW (2008). Bid: a Bax-like BH3 protein. Oncogene 27 Suppl 1: S93-104.
32. Riedl, SJ and Salvesen, GS (2007). The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8: 405-413.
33. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651-659.
34. Liu, C, Russell, SJ and Peng, KW (2010). Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 18: 1155-1164.
35. Césaire, R, Olière, S, Sharif-Askari, E, Loignon, M, Lézin, A, Olindo, S et al. (2006). Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene 25: 349-358.
36. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
37. Ebert, O, Harbaran, S, Shinozaki, K and Woo, SL (2005). Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 12: 350-358.
38. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, BD et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.
39. Inoue, S, Riley, J, Gant, TW, Dyer, MJ and Cohen, GM (2007). Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21: 1773-1782.
40. Gomez-Bougie, P, Wuillème-Toumi, S, Ménoret, E, Trichet, V, Robillard, N, Philippe, M et al. (2007). Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67: 5418-5424.
41. Pérez-Galán, P, Roué, G, López-Guerra, M, Nguyen, M, Villamor, N, Montserrat, E et al. (2008). BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 22: 1712-1720.
42. Nencioni, A, Hua, F, Dillon, CP, Yokoo, R, Scheiermann, C, Cardone, MH et al. (2005). Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105: 3255-3262.
43. Iglesias-Serret, D, Piqué, M, Barragán, M, Cosialls, AM, Santidrián, AF, González-Gironès, DM et al. (2010). Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis 15: 219-229.
44. Kuwana, T, Bouchier-Hayes, L, Chipuk, JE, Bonzon, C, Sullivan, BA, Green, DR et al. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535.
45. Lovell, J F, Billen, L P, Bindner, S, Shamas-Din, A, Fradin, C, Leber, B et al. (2008). Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135: 1074-1084.
46. Gavathiotis, E, Suzuki, M, Davis, ML, Pitter, K, Bird, GH, Katz, SG et al. (2008). BAX activation is initiated at a novel interaction site. Nature 455: 1076-1081.
47. Liang, X, Moseman, EA, Farrar, MA, Bachanova, V, Weisdorf, DJ, Blazar, BR et al. (2010). Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115: 5041-5052.
48. Abbott, BL (2006). Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 11: 21-30.
49. Abbott, BL (2006). Recent advances in chronic lymphocytic leukemia. Cancer Invest 24: 302-309.
50. Jensen, MM, Jørgensen, JT, Binderup, T and Kjaer, A (2008). Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 8: 16.